Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Clinical Trials
1.1k
Trial Phases
5 Phases
Drug Approvals
55
Drug Approvals
EXELON 9.5MG-24H TRANSDERMAL PATCHES
- Approval Date
- Jul 18, 2025
- Company
- lts lohmann therapie-systeme
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
Distribution across different clinical trial phases (1017 trials with phase data)• Click on a phase to view related trials
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 435
- Registration Number
- NCT06705504
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Conditions
- Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42494
- Registration Number
- NCT06671314
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 376
- Registration Number
- NCT06662825
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1665
- Registration Number
- NCT06662812
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3632
- Registration Number
- NCT06644638
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 143
- Next
News
FDA Approves Remibrutinib as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria
The FDA has approved remibrutinib (Rhapsido) as the first oral Bruton's tyrosine kinase inhibitor for treating chronic spontaneous urticaria in adults who remain symptomatic despite antihistamine therapy.
Cue Biopharma Appoints Dr. Usman Azam as CEO, Pivots to Autoimmune Disease Focus with CUE-401
Cue Biopharma has appointed Dr. Usman Azam as President and CEO, effective September 29, 2025, bringing over 25 years of drug development experience including CAR-T cell therapy leadership at Novartis.
Novartis Launches Direct-to-Patient Platform for Cosentyx with 55% Discount in US
Novartis will launch a direct-to-patient platform on November 1, 2025, offering Cosentyx at a 55% discount off list price to cash-paying patients in the US.
Moonlake's Sonelokimab Falls Short in Hidradenitis Suppurativa Trials, Shares Plummet 80%
Moonlake Immunotherapeutics' experimental drug sonelokimab delivered mixed results in two late-stage hidradenitis suppurativa trials, with one study meeting statistical significance but falling short of investor expectations.
MannKind Appoints Dr. Ajay Ahuja as Chief Medical Officer to Advance Inhaled Therapeutics Pipeline
MannKind Corporation has appointed Dr. Ajay Ahuja as Chief Medical Officer, bringing over two decades of biopharmaceutical leadership experience to advance the company's inhaled therapeutics pipeline.
Amneal Submits BLA for Omalizumab Biosimilar to Challenge $4.1 Billion XOLAIR Market
Amneal Pharmaceuticals has submitted a Biologics License Application to the FDA for a biosimilar to XOLAIR (omalizumab), developed in partnership with Kashiv BioSciences.
Tiziana Life Sciences Advances IL-6 Receptor Antibody TZLS-501 Following Novartis' $1.4B Tourmaline Acquisition
Tiziana Life Sciences announces advancement of TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R with dual mechanism of action.
Myricx Bio Appoints New CEO as Company Advances Novel ADC Platform Toward Clinical Trials
Myricx Bio has appointed Mohit Rawat as CEO, bringing extensive biopharma experience from Fusion Pharmaceuticals, which was acquired by AstraZeneca for $2.4 billion in 2024.
Celltrion Launches First Omalizumab Biosimilar Omlyclo in Europe, Starting with Norway
Celltrion has become the first pharmaceutical company to launch Omlyclo, an omalizumab biosimilar referencing Xolair, in the European market starting with Norway.
Advanced Drug Delivery Technologies Drive Biotech Innovation as Nanomedicine Market Approaches $430 Billion
The global nanomedicine market is projected to grow from approximately $245 billion in 2023 to over $430 billion by 2028, driven by increasing adoption in oncology, neurology, and regenerative medicine.